Pain Management Drugs Market is Growing Exponentially in Order to Gain More Demand by 2027

The Pain Management Drugs Market 2021 – 2027 report covers the important factors driving the growth of the market, untapped opportunities for manufacturers, trends and developments shaping the dynamics of the market and other insights across various key segments.

Request Here For PDF Brochure

The global pain management drugs market, by Drug Class (Opioids, NSAIDs, Anticonvulsants, Antidepressants, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 63,212.3 Mn in 2017 and is projected to exhibit a CAGR of 3.9% over the forecast period (2018–2026).

The pain management medicines market is predicted to rise due to the availability of a large range of pain management pharmacological products (both generic and branded), the lack of alternative therapies, and ongoing research and development of new therapies. In 2017, Lupin Pharmaceuticals released a generic version of Allergan’s Norco (hydrocodone/acetaminophen) in the United States. In 2017, Daiichi Sankyo Company, Limited released Narurapid (hydromorphone hydrochloride) tablets and Narusus tablets for cancer pain therapy. The medicine Zilretta for arthritic knee pain was approved by the United States Food and Drug Administration (FDA) in 2017. Manufacturers are putting a lot of effort into integrating healthcare IT to help doctors control pain. In February 2018, for example, 2Morrow, Inc., a digital therapeutics business, released a pain management app. Avella is a company that specialises in treating pain and addiction. Management mobile app for physicians in 2017. These applications will aid clinicians in the management of their patients as well as the prevention of opioid (pain-relieving) addiction. This is likely to boost pain management drug adoption rates over the forecast period, propelling the market for pain management pharmaceuticals forward. Ongoing research & development for novel pain management drugs is expected to enhance market growth. Trevena, Inc. is working on two potential pain-relieving drugs. TRV734 (Phase I) for moderate to severe pain (NDA approved by the USFDA in January 2018) and oliceridine injection for moderate to severe acute pain (NDA approved by the USFDA in January 2018). For chronic pain, Cara Therapeutics has the medicines CR845/oral difelikefalin (Phase II) and Oral CR701 (preclinical phase). Arena Pharmaceuticals is also testing Olorinab (APD371) for Crohn’s disease in Phase II clinical studies. Furthermore, Pfizer, Inc. and Eli Lilly and Company are attempting to acquire approval for Tanezumab, a humanised monoclonal immunoglobulin G2 antibody, which is now in phase III clinical trials for the treatment of persistent low back pain and osteoarthritis pain. Targeted immunotherapies, for example, have less adverse effects than traditional therapies, and their approval is projected to dramatically alter pain medication management over the forecast period.

Key Takeaways of the Pain Management Drugs Market:

• Due to increased product launches by generic manufacturers such as Lupin and others, the worldwide pain management medicines market is predicted to grow at a CAGR of 3.9 percent over the forecast period (2018–2026). Among drug class, opioids segment is expected to dominate the pain management drugs market over the forecast period

• Majority of the drugs in the pain management drugs market has lost patent protection due to which generic manufacturers have been able to enter into the market

Major Key Players Include In Pain Management Drugs Market: Pfizer, Inc., Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Abbott Laboratories, Purdue Pharma L.P., GlaxoSmithKline Plc, Johnson & Johnson, and F. Hoffmann La Roche Ltd.

Buy instant copy of this research report with Flat US $ 2000 Off@ – https://www.coherentmarketinsights.com/promo/buynow/1697

Main points in Pain Management Drugs Market Report Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Pain Management Drugs Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Pain Management Drugs Industry Impact

Chapter 2 Global Pain Management Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Pain Management Drugs (Volume and Value) by Type
2.3 Global Pain Management Drugs (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Pain Management Drugs Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Pain Management Drugs Market Analysis
Chapter 6 East Asia Pain Management Drugs Market Analysis
Chapter 7 Europe Pain Management Drugs Market Analysis
Chapter 8 South Asia Pain Management Drugs Market Analysis
Chapter 9 Southeast Asia Pain Management Drugs Market Analysis
Chapter 10 Middle East Pain Management Drugs Market Analysis
Chapter 11 Africa Pain Management Drugs Market Analysis
Chapter 12 Oceania Pain Management Drugs Market Analysis
Chapter 13 South America Pain Management Drugs Market Analysis
Chapter 14 Company Profiles and Key Figures in Pain Management Drugs Business
Chapter 15 Global Pain Management Drugs Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology

Request for a Sample Report

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com